Please login to the form below

Not currently logged in
Email:
Password:

GSK loses Viani patent case in Germany

The Federal Patents Court in Germany has ruled against GlaxoSmithKline regarding its patent for Viani, a treatment for asthma and COPD

The Federal Patents Court in Munich, Germany has ruled against GlaxoSmithKline (GSK) regarding its patent for Viani (Seretide), an inhaled respiratory treatment for asthma and chronic obstructive pulmonary disease (COPD).

Mylan, Hexal (part of Novartis' Sandoz), Neolab, and IVAX (owned by Teva) brought the case against GSK to Court.

The Court concluded that under German law GSK's German combination patent for Viani (relating to the combination of the active ingredients salmeterol and fluticasone propionate) was not valid.

GSK is studying the judgment and will be considering an appeal to a higher court.

In a statement, GSK said that "the decision relates solely to the German combination patent for Viani and is not binding in any other jurisdiction". 

GSK holds a number of other Viani-related patents in Germany, including patents for the Diskus dry powder inhaler and HFA aerosol formulation, which expire in 2011 and 2012, respectively.

Viani is also known as Advair in other markets. In 2009, the drug accounted for 18 per cent of GSK's revenue and posted sales of $7.8bn.

20th May 2010

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Hanover Communications

Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...

Latest intelligence

Report: Reinventing product and portfolio value for the biopharmaceutical industry
Gain practical advice on determining and communicating product and portfolio value, including why, in fast-paced and evolving markets, you need to consider the evidence requirements of a growing network of...
Neil Thompson
How AI is finally helping rare diseases gain more than just attention
By Neil Thompson...
Is communication failing us?
Compelling people to care in a world oversaturated with news and information...